Detalhe da pesquisa
1.
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.
Mol Cancer Ther
; 4(6): 948-55, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15956252